Innate immune responses to Stenotrophomonas maltophilia in immunocompromised pediatric patients and the effect of taurolidine

Journal of Microbiology, Immunology and Infection

Volumn 46, Issue 2, 2013, Pages 115-120

  Härtel, Christoph ^a   Scholz, Tasja ^a   Kuhn, Marie ^a   Bendiks, Meike ^a   Göpel, Wolfgang ^a   Lauten, Melchior ^a   Herting, Egbert ^a  

^a UNIVERSITY OF LÜBECK   (Germany)

Author keywords

Cytokines; Flow cytometry; Neonates; Neonatology; Oncology; Pediatrics; Stenotrophomonas maltophilia; Taurolidine

Indexed keywords

CD14 ANTIGEN; INTERLEUKIN 6; INTERLEUKIN 8; TAUROLIDINE; TUMOR NECROSIS FACTOR ALPHA;

ADOLESCENT; ARTICLE; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; FLOW CYTOMETRY; HUMAN; IMMUNOCOMPROMISED PATIENT; IMMUNOMODULATION; IN VITRO STUDY; INNATE IMMUNITY; NEUTROPENIA; NEWBORN; PROTEIN EXPRESSION; SCHOOL CHILD; SEPSIS; STENOTROPHOMONAS MALTOPHILIA;

ADULT; ANTIGENS, CD14; ANTINEOPLASTIC AGENTS; CYTOKINES; FEMALE; FLOW CYTOMETRY; HEMATOLOGIC NEOPLASMS; HUMANS; IMMUNITY, INNATE; IMMUNOCOMPROMISED HOST; IMMUNOSUPPRESSION; IMMUNOSUPPRESSIVE AGENTS; INFANT, NEWBORN; LEUKOCYTES; MALE; MODELS, THEORETICAL; STENOTROPHOMONAS MALTOPHILIA; TAURINE; THIADIAZINES;

EID: 84876134817     PISSN: 16841182     EISSN: 19959133     Source Type: Journal    
DOI: 10.1016/j.jmii.2012.04.002     Document Type: Article

References (25)

1. Chaplow R., Palmer B., Heyderman R., Moppett J., Marks D.I. Stenotrophomonas maltophilia bacteremia in 40 haematology patients: risk factors, therapy, outcome. Bone Marrow Transplant 2010, 45:11109-11110.
2. Mutlu M., Yilmaz G., Aslan Y., Bayramoglu G. Risk factors and clinical characteristics of Stenotrophomonas maltophilia infections in neonates. J Microbiol Immunol Infect 2011, 44:467-472.
3. Falagas M.E., Valkimadi P., Huang Y.T., Matthaiou D.K., Hseuh P.R. Therapeutic options for stenotrophomonas maltophilia beyond co-trimoxazole: a systematic review. J Antimicrob Chemoth 2008, 62:889-894.
4. Blenkharn J.I. In vitro antibacterial activity of noxythiolin and taurolidin. J Pharm Pharmacol 1990, 42:589-590.
5. Traub W.H., Leonhard B., Bauer D. Taurolidine: in vitro activity against multiple-antibiotic-resistant, nosocomially significant clinical isolates of Staphylococcus aureus, Enterococcus faecium, and diverse Enterobacteriaceae. Chemotherapy 1993, 39:322-330.
6. Torres-Viera C., Thauvin-Eliopoulos C., Souli M., DeGirolami P., Farris M.G., Wennersten C.B., et al. Activities of taurolidine in vitro and in experimental enterococcal endocarditis. Antimicrob Agents Chemother 2000, 44:1720-1724.
7. Browne M.K., Leslie G.B., Pfirrmann R.W. Taurolidin a new chemotherapeutic agent. J Appl Bacteriol 1976, 41:363-368.
8. Shah C.B., Mittelman M.W., Costerton J.W. Antimicrobial activity of a novel catheter lock solution. Antimicrob Agents Chemother 2002, 46:1674-1679.
9. Gorman S.P., McCafferty D.F., Woolfson A.D., Jones D.S. A comparative study of the microbial antiadherence capacities of three antimicrobial agents. J Clin Pharm Ther 1987, 12:393-399.
10. Bedrosian I., Sofia R.D., Wolff S.M., Dinarello C.A. Taurolidine, an analogue of the amino acid taurine, suppresses interleukin 1 and tumor necrosis factor synthesis in human peripheral blood mononuclear cells. Cytokine 1991, 3:568-575.
11. Watson R.W., Redmond H.P., McCarthy J., Bouchier-Hayes D. Taurolidine, an antilipopolysaccharide agent, has immunoregulatory properties that are mediated by the amino acid taurine. J Leuko Biol 1995, 58:299-306.
12. Schultz C. Intracytoplasmatic detection of proinflammatory cytokines and chemokines in monocytes by flow cytometry. Methods Mol Biol 2003, 215:29-39.
13. Levy O. Innate immunity of the newborn: basic mechanisms and clinical correlates. Nat Rev Immunol 2007, 7:379-390.
14. Härtel C., Adam N., Temming P., Strunk T., Müller-Steinhardt M., Schultz C. Cytokine responses differentially correlate with age in infancy and early childhood. Clin Exp Immunol 2005, 142:446-453.
15. Härtel C., Schultz C., Göpel W., Herting E. Genetic association studies in VLBW infants exemplifying susceptibility to sepsis-recent findings and implications for future research. Acta Paediatr 2007, 96:158-165.
16. Borella L., Green A., Webster R. Immunologic rebound after cessation of long-term chemotherapy in acute leukaemia. Blood 1972, 40:42-45.
17. Brodtman D.H., Rosenthal D.W., Redner A., Lanzkowsky P., Bonagura V.R. Immunodeficiency in children with acute lymphoblastic leukaemia after completion of modern aggressive chemotherapeutic regimens. J Pediatr 2005, 146:654-661.
18. Nilsson A., De Milito A., Engström P., Nordin M., Marita M., Grillner L., et al. Current chemotherapy protocols for childhood acute lymphoblastic leukemia induce loss of humoral immunity to viral vaccination antigens. Pediatrics 2002, 109:e91.
19. Härtel C., Deuster M., Lehrnbecher T., Schultz C. Current approaches for risk stratification of infectious complications in pediatric oncology. Ped Blood Cancer 2007, 49:767-773.
20. Nicodemo A.C., Paez J.I. Antimicrobial therapy for Stenotrophomonas maltophilia infections. Eur J Clin Microbiol Infect Dis 2007, 26:229-237.
21. Faust K., Göpel W., Herting E., Härtel C. Sepsis bei Frühgeborenen mit einem sehr niedrigen Geburtsgewicht. Chemotherapy J 2011, 20:1-8.
22. Allon M. Prophylaxis against dialysis catheter-related bacteremia with a novel antimicrobial lock solution. Clin Infect Dis 2003, 36:1539-1544.
23. Koldehoff M., Zakrzewski J.L. Taurolidine is effective in the treatment of central venous catheter-related bloodstream infections in cancer patients. Int J Antimicrob Agents 2004, 24:491-495.
24. Beutel K., Simon A. Diagnostic and management of central venous line infections in pediatric cancer patients. Klin Pädiatr 2005, 217(Suppl. 1):91-100.
25. Simon A., Ammann R.A., Bode U., Fleischhack G., Wenchel H.M., Schwamborn D., et al. Healthcare-associated infections in pediatric cancer patients: results of a prospective surveillance study from university hospitals in Germany and Switzerland. BMC Infect Dis 2008, 8:70.